Formula (Lyllana Estradiol Transdermal System 1)
Lyllana Patch, Extended Release
Product Images NDC 65162-149
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Lyllana (NDC 65162-149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure D (Lyllana Estradiol Transdermal System 10)
Figure E (Lyllana Estradiol Transdermal System 11)
Figure F (Lyllana Estradiol Transdermal System 12)
Figure G (Lyllana Estradiol Transdermal System 13)
0.025 mg/day Pouch (Lyllana Estradiol Transdermal System 14)
LYLLANA is a transdermal system used for delivering estradiol in a dosage strength of 0.025 mg/day. The system contains 0.314 mg of estradiol and uses a combination of acrylic and silicone adhesive, oleyl alcohol, dipropylene glycol, povidone, polyester, and ethylene vinyl acetate copolymer film, and polyester release liner. It is important to note that the package is not child-resistant and should be kept out of reach of children. The system should be applied immediately after removing it from the pouch, and it should not be stored unpouched. The product is distributed by Amneal Pharmaceuticals LLC and must be stored between 20-25°C (68-77°F), with excursions allowed between 15-30°C (59-86°F).*
0.025 mg/day Carton (Lyllana Estradiol Transdermal System 15)
0.0375 mg/day Pouch (Lyllana Estradiol Transdermal System 16)
LYLLA NA™ is a transdermal system that contains 0.470 mg of estradiol, USP that delivers 0.0375 mg/day. It is supplied in a 2.83 cm² system and contains inactive components such as acrylic adhesive, silicone adhesive, oleyl alcohol, dipropylene glycol, povidone, polyester and ethylene vinyl acetate copolymer film, polyester release liner. The package is not child-resistant and must be kept out of the reach of children. LYLLA NA™ must be applied immediately upon removal from the pouch and must not be stored unpouched. It is distributed by Amneal Pharmaceuticals LLC and must be stored at 20° to 25°C (68° to 77°F) with some excursions permitted.*
0.0375 mg/day Carton (Lyllana Estradiol Transdermal System 17)
0.05 mg/day Pouch (Lyllana Estradiol Transdermal System 18)
0.05 mg/day Carton (Lyllana Estradiol Transdermal System 19)
This is a description of a medication product. The product consists of 8 systems, each containing 3.78 ounces which controls 0.627 grams of Estadio, LS. The product is for transdermal use only and is packaged with important instructions. Dosage and administration information is provided in the package insert. Information on inactive components is provided. The product is distributed by Aveal Pharmaceuticals LLC in NJ, USA. The rest of the text is unclear and not readable due to errors.*
3 Layers (Lyllana Estradiol Transdermal System 2)
This is a product description for a type of adhesive that contains the hormone Estradiol. The product also features a protective liner and a backing material, although specific details about these components are not provided.*
0.075 mg/day Pouch (Lyllana Estradiol Transdermal System 20)
7LYLLANA is a prescription-only estradiol transdermal system that delivers 0.075 mg/day. Each system contains 0.940 mg of estradiol, USP, along with inactive components like acrylic adhesive, silicone adhesive, oleyl alcohol, dipropylene glycol, povidone, polyester, and ethylene vinyl acetate copolymer film. The package is not child-resistant, and the system should be applied immediately upon removal from the pouch, as it should not be stored unpouched. It should be stored at a controlled room temperature of 20° to 25°C (68° to 77°F), with excursions permitted between 15° to 30°C (59° to 86°F). The product is distributed by Amneal Pharmaceuticals LLC.*
0.075 mg/day Carton (Lyllana Estradiol Transdermal System 21)
0.1 mg/day Pouch (Lyllana Estradiol Transdermal System 22)
7LYLLA NA™ NDC 651 82~228~047 is a prescription-only transdermal system that delivers 0.1 mg/day of estradiol USP. Each system is 7.55 cm2 and contains 1.253 mg of estradiol USP along with inactive components such as acrylic adhesive, silicone adhesive, oleyl alcohol, dipropylene glycol, povidone, polyester, and ethylene vinyl acetate copolymer film, polyester release liner. It is important to keep this package out of the reach of children and apply it immediately upon removal from the pouch. Do not store unpouched. The system should be stored at 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. It is distributed by Amneal Pharmaceuticals LLC in Bridgewater, NJ.*
0.1 mg/day Carton (Lyllana Estradiol Transdermal System 23)
Figure 1 (Lyllana Estradiol Transdermal System 3)
Figure 2 (Lyllana Estradiol Transdermal System 4)
The text describes data related to a reduction from a certain baseline, measured in an unknown unit called "an(sD)". There is also information about a specific dosage of "0.0375 mg/day" of something called "Vivete". The word "placebo" is mentioned, and it seems to indicate some sort of statistical difference between the effects of this placebo and the effects of Vivelle an. However, without more context or information, it's difficult to determine the nature of the study, what Vivete and Vivelle are, or what the reduction from baseline actually represents.*
Figure 3 (Lyllana Estradiol Transdermal System 5)
Figure 4 (Lyllana Estradiol Transdermal System 6)
Figure A (Lyllana Estradiol Transdermal System 7)
Figure B (Lyllana Estradiol Transdermal System 8)
LYLLANA is a pharmaceutical product containing the active ingredient estradiol. The given characters "ol ywom.5P)" are not readable and may be a result of incorrect .*
Figure C (Lyllana Estradiol Transdermal System 9)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
